Switch theme
Sign up to access all valuation multiples
Torrent Pharmaceuticals Ltd is a drug manufacturing company with a focus on the cardiovascular, central nervous system, and gastrointestinal therapeutic areas. It operates through the Generic Formulation Business segment. Geographically, the business activities are carried out across Indian and International markets. Maximum revenue for the company is generated from its operations in India.
1972
14.9K+
LTM Revenue $1.4B
LTM EBITDA $448M
$12.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Torrent Pharma has a last 12-month revenue (LTM) of $1.4B and a last 12-month EBITDA of $448M.
In the most recent fiscal year, Torrent Pharma achieved revenue of $1.3B and an EBITDA of $436M.
Torrent Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Torrent Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.4B | XXX | $1.3B | XXX | XXX | XXX |
| Gross Profit | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| Gross Margin | 76% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | $448M | XXX | $436M | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| EBIT | $354M | XXX | $343M | XXX | XXX | XXX |
| EBIT Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| Net Profit | $238M | XXX | $224M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $287M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Torrent Pharma's stock price is INR 3175 (or $37).
Torrent Pharma has current market cap of INR 1.07T (or $12.6B), and EV of INR 1.10T (or $12.9B).
See Torrent Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.9B | $12.6B | XXX | XXX | XXX | XXX | $0.70 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Torrent Pharma has market cap of $12.6B and EV of $12.9B.
Torrent Pharma's trades at 9.9x EV/Revenue multiple, and 30.0x EV/EBITDA.
Equity research analysts estimate Torrent Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Torrent Pharma has a P/E ratio of 52.9x.
See valuation multiples for Torrent Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.6B | XXX | $12.6B | XXX | XXX | XXX |
| EV (current) | $12.9B | XXX | $12.9B | XXX | XXX | XXX |
| EV/Revenue | 9.4x | XXX | 9.9x | XXX | XXX | XXX |
| EV/EBITDA | 28.7x | XXX | 30.0x | XXX | XXX | XXX |
| EV/EBIT | 36.3x | XXX | 38.7x | XXX | XXX | XXX |
| EV/Gross Profit | 12.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 52.9x | XXX | 58.2x | XXX | XXX | XXX |
| EV/FCF | 51.4x | XXX | 50.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTorrent Pharma's last 12 month revenue growth is 12%
Torrent Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $44K for the same period.
Torrent Pharma's rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Torrent Pharma's rule of X is 64% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Torrent Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 14% | XXX | XXX | XXX |
| Rule of 40 | 45% | XXX | 45% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 64% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $44K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 50% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Torrent Pharma acquired XXX companies to date.
Last acquisition by Torrent Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Torrent Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Torrent Pharma founded? | Torrent Pharma was founded in 1972. |
| Where is Torrent Pharma headquartered? | Torrent Pharma is headquartered in India. |
| How many employees does Torrent Pharma have? | As of today, Torrent Pharma has 14.9K+ employees. |
| Is Torrent Pharma publicy listed? | Yes, Torrent Pharma is a public company listed on NSE. |
| What is the stock symbol of Torrent Pharma? | Torrent Pharma trades under TORNTPHARM ticker. |
| When did Torrent Pharma go public? | Torrent Pharma went public in 2002. |
| Who are competitors of Torrent Pharma? | Similar companies to Torrent Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Torrent Pharma? | Torrent Pharma's current market cap is $12.6B |
| What is the current revenue of Torrent Pharma? | Torrent Pharma's last 12 months revenue is $1.4B. |
| What is the current revenue growth of Torrent Pharma? | Torrent Pharma revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Torrent Pharma? | Current revenue multiple of Torrent Pharma is 9.4x. |
| Is Torrent Pharma profitable? | Yes, Torrent Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Torrent Pharma? | Torrent Pharma's last 12 months EBITDA is $448M. |
| What is Torrent Pharma's EBITDA margin? | Torrent Pharma's last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of Torrent Pharma? | Current EBITDA multiple of Torrent Pharma is 28.7x. |
| What is the current FCF of Torrent Pharma? | Torrent Pharma's last 12 months FCF is $250M. |
| What is Torrent Pharma's FCF margin? | Torrent Pharma's last 12 months FCF margin is 18%. |
| What is the current EV/FCF multiple of Torrent Pharma? | Current FCF multiple of Torrent Pharma is 51.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
